Canakinumab treatment in four children with colchicine resistant familial mediterranean fever

Basit Öğe Kaydı
dc.contributor.authorOzkan, Solmaz
dc.contributor.authorAtas, Bulent
dc.date.accessioned2024-02-23T14:48:59Z
dc.date.available2024-02-23T14:48:59Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractFamilial Mediterranean Fever (FMF) is an autosomal recessive and autoinflammatory disease, characterized with inflammation of serous membranes such as peritoneum, pleura, synovium with fever and pain. Colchicine is the main treatment of FMF, but 5-10 % of patients are unresponsive to colchicine. We report using anti-interleukin-1 agents anakinra and canakinumab in four colchicine-resistant patients who were successfully treated. Three of the patients were siblings.en_US
dc.identifier.endpage947en_US
dc.identifier.issn0030-9982
dc.identifier.issue6en_US
dc.identifier.pmid28585601en_US
dc.identifier.scopus2-s2.0-85019177052en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage945en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/17933
dc.identifier.volume67en_US
dc.identifier.wosWOS:000402866300027en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPakistan Medical Assocen_US
dc.relation.ispartofJournal Of The Pakistan Medical Associationen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFamilial Mediterranean Feveren_US
dc.subjectAnakinraen_US
dc.subjectCanakinumaben_US
dc.titleCanakinumab treatment in four children with colchicine resistant familial mediterranean feveren_US
dc.typeEditorial Materialen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu